Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

被引：0

作者：

Philippe Moreau

Ievgenii I. Karamanesht

Natalia Domnikova

Maryna Y. Kyselyova

Kateryna V. Vilchevska

Vadim A. Doronin

Alexander Schmidt

Cyrille Hulin

Xavier Leleu

Dixie-Lee Esseltine

Karthik Venkatakrishnan

Donna Skee

Huaibao Feng

Suzette Girgis

Andrew Cakana

Helgi van de Velde

William Deraedt

Thierry Facon

机构：

[1] University Hospital,Hematology Department

[2] Kiev BMT Centre,Hematology Department

[3] State Novosibirsk Regional Clinical Hospital,undefined

[4] Crimean Republic Clinical Oncology Dispensary,undefined

[5] Haematology Department,undefined

[6] V.K. Gusak Institute of Urgent and Recovery Surgery,undefined

[7] Academy of Medical Science,undefined

[8] City Clinical Hospital #40,undefined

[9] Hematology Department,undefined

[10] Russian Research Institute of Hematology and Transfusiology,undefined

[11] Centre Hospitalier Universitaire Nancy,undefined

[12] Hôpital Claude Huriez,undefined

[13] Centre Hospitalier Régional Universitaire de Lille,undefined

[14] Millennium Pharmaceuticals,undefined

[15] Inc.,undefined

[16] Janssen Research & Development,undefined

[17] Janssen Research & Development,undefined

[18] Janssen Research & Development,undefined

[19] Janssen Research & Development,undefined

来源：

Clinical Pharmacokinetics | 2012年 / 51卷

关键词：

Multiple Myeloma; Bortezomib; Mantle Cell Lymphoma; Alemtuzumab; Subcutaneous Administration;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：823 / 829

页数：6

共 60 条

[1]

Moreau P(2011)Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 431-440

[2]

Pylypenko H(2008)Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma Haematologica 93 1908-1911

[3]

Grosicki S(2005)International staging system for multiple myeloma J Clin Oncol 23 3412-3420

[4]

Karamanesht I(2000)Proteasome inhibition measurements: clinical application Clin Chem 46 673-683

[5]

Leleu X(2002)Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 100 768-773

[6]

Grishunina M(2009)Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin’s lymphoma or multiple myeloma Clin Pharmacokinet 48 199-209

[7]

Moreau P(2009)Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug–drug interaction study Clin Ther 31 2444-2458

[8]

Coiteux V(2011)Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin’s lymphoma Clin Pharmacokinet 50 781-791

[9]

Hulin C(2011)Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study Cancer Chemother Pharmacol 68 1439-1447

[10]

Leleu X(2012)Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432 Clin Cancer Res 18 2954-2963

← 1 2 3 4 5 6 →